

AD-A247 956



2

AD _____

ARMY PROJECT ORDER NO: 90PP0813


TITLE: DEVELOPMENT OF SAFE, EFFECTIVE VACCINES FOR DENGUE VIRUS
DISEASE BY RECOMBINANT BACULOVIRUS

SUBTITLE: Development of Safe, Effective Vaccines for Dengue
Disease Utilizing Viral Envelope and NSI Glycoproteins
Expressed by Recombinant Baculovirus

PRINCIPAL INVESTIGATOR: Ching-Juh Lai, Ph.D.

CONTRACTING ORGANIZATION: National Institutes of Health
Molecular Viral Biology Section
Laboratory of Infectious Diseases
9000 Rockville Pike
Bethesda, MD 20892

REPORT DATE: September 16, 1991



TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The findings in this report are not to be construed as an
official Department of the Army position unless so designated by
other authorized documents.

92-06779



REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
<small>Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.</small>				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE 16 September 1991	3. REPORT TYPE AND DATES COVERED Annual Report (3/1/90 - 2/28/91)	
4. TITLE AND SUBTITLE DEVELOPMENT OF SAFE, EFFECTIVE VACCINES FOR DENGUE VIRUS DISEASE BY RECOMBINANT BACULOVIRUS			5. FUNDING NUMBERS Army Project Order 90PP0813 61102A 3M161102BS13.AA.045 WUDA335461	
6. AUTHOR(S) Ching-Juh Lai, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) National Institutes of Health Molecular Viral Biology Section Laboratory of Infectious Diseases 9000 Rockville Pike Bethesda, MD 20892			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Frederick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Subtitle: Development of Safe, Effective Vaccines for Dengue Disease Utilizing Viral Envelope and NS1 Glycoproteins Expressed by Recombinant Baculovirus				
12a. DISTRIBUTION AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) During the initial phase of this study we have completed construction of recombinant baculoviruses that separately express full-length E or NS1 glycoprotein of dengue type 2 and type 4 viruses. Radio-immunoprecipitation was performed to analyze the dengue product in the lysate of recombinant virus infected cells. The results showed that insect cells infected with recombinant b(DEN 4, 100%E) produced a protein with molecular weight of 55-60 kilodalton (Kd) as predicted for the glycosylated form of dengue E glycoprotein. Similarly, recombinant b(DEN 4, NS1) or b(DEN 2, NS1) produced a protein in infected insect cells that was approximately 40-44 Kd, the size predicted for the dengue NS1 glycoprotein. In the next phase of this study we plan to prepare lysates of insect cells infected with various recombinant				
14. SUBJECT TERMS Dengue Virus; Genetic Engineering; Recombinant DNA; Vaccines Lab Animals; RAI			15. NUMBER OF PAGES	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

13. Abstract (continued)

baculoviruses. These lysates will be analyzed quantitatively and used for evaluation of immunogenicity of the expressed dengue protein products in mice. These studies will allow us to determine separately the protective efficacy afforded by each of these dengue virus proteins, and therefore, select the most immunogenic as well as the most protective recombinant products for further evaluation in primates.

Accession For	
101-101	<input checked="checked" type="checkbox"/>
101-102	<input type="checkbox"/>
101-103	<input type="checkbox"/>
101-104	
101-105	
101-106	
101-107	
101-108	
101-109	
101-110	
101-111	
101-112	
101-113	
101-114	
101-115	
101-116	
101-117	
101-118	
101-119	
101-120	
101-121	
101-122	
101-123	
101-124	
101-125	
101-126	
101-127	
101-128	
101-129	
101-130	
101-131	
101-132	
101-133	
101-134	
101-135	
101-136	
101-137	
101-138	
101-139	
101-140	
101-141	
101-142	
101-143	
101-144	
101-145	
101-146	
101-147	
101-148	
101-149	
101-150	
101-151	
101-152	
101-153	
101-154	
101-155	
101-156	
101-157	
101-158	
101-159	
101-160	
101-161	
101-162	
101-163	
101-164	
101-165	
101-166	
101-167	
101-168	
101-169	
101-170	
101-171	
101-172	
101-173	
101-174	
101-175	
101-176	
101-177	
101-178	
101-179	
101-180	
101-181	
101-182	
101-183	
101-184	
101-185	
101-186	
101-187	
101-188	
101-189	
101-190	
101-191	
101-192	
101-193	
101-194	
101-195	
101-196	
101-197	
101-198	
101-199	
101-200	
101-201	
101-202	
101-203	
101-204	
101-205	
101-206	
101-207	
101-208	
101-209	
101-210	
101-211	
101-212	
101-213	
101-214	
101-215	
101-216	
101-217	
101-218	
101-219	
101-220	
101-221	
101-222	
101-223	
101-224	
101-225	
101-226	
101-227	
101-228	
101-229	
101-230	
101-231	
101-232	
101-233	
101-234	
101-235	
101-236	
101-237	
101-238	
101-239	
101-240	
101-241	
101-242	
101-243	
101-244	
101-245	
101-246	
101-247	
101-248	
101-249	
101-250	
101-251	
101-252	
101-253	
101-254	
101-255	
101-256	
101-257	
101-258	
101-259	
101-260	
101-261	
101-262	
101-263	
101-264	
101-265	
101-266	
101-267	
101-268	
101-269	
101-270	
101-271	
101-272	
101-273	
101-274	
101-275	
101-276	
101-277	
101-278	
101-279	
101-280	
101-281	
101-282	
101-283	
101-284	
101-285	
101-286	
101-287	
101-288	
101-289	
101-290	
101-291	
101-292	
101-293	
101-294	
101-295	
101-296	
101-297	
101-298	
101-299	
101-300	
101-301	
101-302	
101-303	
101-304	
101-305	
101-306	
101-307	
101-308	
101-309	
101-310	
101-311	
101-312	
101-313	
101-314	
101-315	
101-316	
101-317	
101-318	
101-319	
101-320	
101-321	
101-322	
101-323	
101-324	
101-325	
101-326	
101-327	
101-328	
101-329	
101-330	
101-331	
101-332	
101-333	
101-334	
101-335	
101-336	
101-337	
101-338	
101-339	
101-340	
101-341	
101-342	
101-343	
101-344	
101-345	
101-346	
101-347	
101-348	
101-349	
101-350	
101-351	
101-352	
101-353	
101-354	
101-355	
101-356	
101-357	
101-358	
101-359	
101-360	
101-361	
101-362	
101-363	
101-364	
101-365	
101-366	
101-367	
101-368	
101-369	
101-370	
101-371	
101-372	
101-373	
101-374	
101-375	
101-376	
101-377	
101-378	
101-379	
101-380	
101-381	
101-382	
101-383	
101-384	
101-385	
101-386	
101-387	
101-388	
101-389	
101-390	
101-391	
101-392	
101-393	
101-394	
101-395	
101-396	
101-397	
101-398	
101-399	
101-400	
101-401	
101-402	
101-403	
101-404	
101-405	
101-406	
101-407	
101-408	
101-409	
101-410	
101-411	
101-412	
101-413	
101-414	
101-415	
101-416	
101-417	
101-418	
101-419	
101-420	
101-421	
101-422	
101-423	
101-424	
101-425	
101-426	
101-427	
101-428	
101-429	
101-430	
101-431	
101-432	
101-433	
101-434	
101-435	
101-436	
101-437	
101-438	
101-439	
101-440	
101-441	
101-442	
101-443	
101-444	
101-445	
101-446	
101-447	
101-448	
101-449	
101-450	
101-451	
101-452	
101-453	
101-454	
101-455	
101-456	
101-457	
101-458	
101-459	
101-460	
101-461	
101-462	
101-463	
101-464	
101-465	
101-466	
101-467	
101-468	
101-469	
101-470	
101-471	
101-472	
101-473	
101-474	
101-475	
101-476	
101-477	
101-478	
101-479	
101-480	
101-481	
101-482	
101-483	
101-484	
101-485	
101-486	
101-487	
101-488	
101-489	
101-490	
101-491	
101-492	
101-493	
101-494	
101-495	
101-496	
101-497	
101-498	
101-499	
101-500	
101-501	
101-502	
101-503	
101-504	
101-505	
101-506	
101-507	
101-508	
101-509	
101-510	
101-511	
101-512	
101-513	
101-514	
101-515	
101-516	
101-517	
101-518	
101-519	
101-520	
101-521	
101-522	
101-523	
101-524	
101-525	
101-526	
101-527	
101-528	
101-529	
101-530	
101-531	
101-532	
101-533	
101-534	
101-535	
101-536	
101-537	
101-538	
101-539	
101-540	
101-541	
101-542	
101-543	
101-544	
101-545	
101-546	
101-547	
101-548	
101-549	
101-550	
101-551	
101-552	
101-553	
101-554	
101-555	
101-556	
101-557	
101-558	
101-559	
101-560	
101-561	
101-562	
101-563	
101-564	
101-565	
101-566	
101-567	
101-568	
101-569	
101-570	
101-571	
101-572	
101-573	
101-574	
101-575	
101-576	
101-577	
101-578	
101-579	
101-580	
101-581	
101-582	
101-583	
101-584	
101-585	
101-586	
101-587	
101-588	
101-589	
101-590	
101-591	
101-592	
101-593	
101-594	
101-595	
101-596	
101-597	
101-598	
101-599	
101-600	
101-601	
101-602	
101-603	
101-604	
101-605	
101-606	
101-607	
101-608	
101-609	
101-610	
101-611	
101-612	
101-613	
101-614	
101-615	
101-616	
101-617	
101-618	
101-619	
101-620	
101-621	
101-622	
101-623	
101-624	
101-625	
101-626	
101-627	
101-628	
101-629	
101-630	
101-631	
101-632	
101-633	
101-634	
101-635	
101-636	
101-637	
101-638	
101-639	
101-640	
101-641	
101-642	
101-643	
101-644	
101-645	
101-646	
101-647	
101-648	
101-649	
101-650	
101-651	
101-652	
101-653	
101-654	
101-655	
101-656	
101-657	
101-658	
101-659	
101-660	
101-661	
101-662	
101-663	
101-664	
101-665	
101-666	
101-667	
101-668	
101-669	
101-670	
101-671	
101-672	
101-673	
101-674	
101-675	
101-676	
101-677	
101-678	
101-679	
101-680	
101-681	
101-682	
101-683	
101-684	
101-685	
101-686	
101-687	
101-688	
101-689	
101-690	
101-691	
101-692	
101-693	
101-694	
101-695	
101-696	
101-697	
101-698	
101-699	
101-700	
101-701	
101-702	
101-703	
101-704	
101-705	
101-706	
101-707	
101-708	
101-709	
101-710	
101-711	
101-712	
101-713	
101-714	
101-715	
101-716	
101-717	
101-718	
101-719	
101-720	
101-721	
101-722	
101-723	
101-724	
101-725	
101-726	
101-727	
101-728	
101-729	
101-730	
101-731	
101-732	
101-733	
101-734	
101-735	
101-736	
101-737	
101-738	

FOREWORD

Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

 x Where copyrighted material is quoted, permission has been obtained to use such material.

 x Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

 x Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

 x In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

 x For the protection of human subjects, the investigator(s) have adhered to policies of applicable Federal Law 45CFR46.

 x In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

Ching-Juh Lai Sep 16, '91
Principal Investigator's Signature Date
Dr. Ching-Juh Lai

TABLE OF CONTENTS

	Page
Table of Contents	2
Introduction	3
Results	7
a) Expressing of authentic dengue type 4 virus E and nonstructural NS1 glycoproteins	7
b) Analysis of full-length dengue 4 E and NS1 expressed by recombinant baculovirus	8
c) Construction of recombinant baculovirus expressing a high level of dengue 4 NS1	9
d) Construction of recombinant baculovirus expressing dengue 2 E or NS1 glycoprotein	10
e) Dengue virus NS1 expressed by recombinant baculovirus was not detected extracellularly	12
f) Construction of recombinant baculovirus expressing highly immunogenic E	13
Conclusions	15
References	17

INTRODUCTION

Outbreaks and major epidemics of dengue continue to afflict human populations, especially in the tropical and subtropical regions of the world. Dengue viruses, transmitted predominantly by mosquito species of the *Aedes* genus, include four serotypes that are distinguishable by plaque reduction--neutralization with type specific monoclonal antibodies (1,2). Dengue is characterized by fever, rash, severe headache, and joint pain. Its mortality rate is low. However, over the past few decades, a more severe form of dengue, characterized by hemorrhage and shock has been observed with increasing frequency in children and young adults. This severe form of dengue has a high mortality rate. Despite years of intensive research, an effective vaccine is still not available for prevention of dengue infection. For these reasons, research on dengue viruses and development of safe and effective vaccines have been given a high priority by the World Health Organization.

Similar to other members of the flavivirus family, dengue virus contains a positive RNA genome and three structural proteins, i.e. capsid protein (C), the small membrane protein (M), and the large membrane or envelope (E) glycoprotein. The RNA genome codes for a long polyprotein that is co- and post-translationally cleaved to produce the three structural proteins and a series of non-structural proteins designated NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 in that order.

One of our research goals has been to develop a safe and effective vaccine for prevention of dengue virus infection. Earlier, we constructed recombinant vaccinia virus that contained dengue type 4 virus cDNA coding for the C-PreM-E-NS1-NS2A polyprotein. Infection of CV-1 cells with this recombinant virus produced apparently authentic PreM, E, and NS1 glycoproteins (3). Mice immunized with this recombinant vaccinia virus were completely protected against lethal dengue encephalitis (4). This successful effort prompted us to construct recombinant baculovirus b(C-PreM-E-NS1-NS2A) that contained the same cDNA coding for polyprotein C-PreM-E-NS1-NS2A. Immunization of mice with the lysate prepared from the recombinant virus infected-insect cells induced complete or nearly complete resistance to lethal intracerebral dengue virus challenge (5). Analysis of seroresponse showed that immunized mice developed a high level of antibodies specific for NS1, whereas antibodies to E or PreM were low or not detected. In order to clarify the role of E in inducing resistance to dengue virus challenge, recombinant baculovirus b(RSVG-E) expressing only E was constructed utilizing the amino terminal 71 amino acid sequence of respiratory syncytial virus (RSV) G glycoprotein as a signal for proper glycosylation of E. Mice immunized with a lysate of insect sf9 cells infected with this recombinant virus failed to develop a detectable seroresponse to E, nevertheless, these mice were completely resistant to dengue virus challenge (6). These observations indicate that the E glycoprotein is a major

protective antigen but left open the mechanism responsible for resistance.

Immunization of mice with dengue virus NS1 alone was investigated using recombinant vaccinia virus expressing authentic NS1. In this construct the 24 hydrophobic amino acid sequence preceding NS1 and the downstream NS2A sequence were both present in order to achieve authentic synthesis of dengue virus NS1 (7). During studies in mice, this recombinant vaccinia virus induced complete protection against dengue challenge. These results showed that dengue NS1 is an independent protective antigen in mice (8). Recently, the protective efficacy of recombinant baculovirus expressed-dengue virus proteins was evaluated in rhesus monkeys. The results showed that one of three monkeys immunized with dengue virus proteins expressed by recombinant b(C-PreM-E-NS1-NS2A) was protected against dengue virus challenge. Also, only one of three monkeys immunized with dengue E alone expressed by b(RSVG-E) was completely protected (9).

Because only partial protection was observed, it is necessary to analyze the quantitative relationship between the amount of viral proteins used for immunization and the extent of protective effect. The protective efficacy of individual antigens should be separately evaluated, and if necessary, improved through genetic manipulation or addition of an appropriate carrier. A stoichiometric analysis may require greater amounts of dengue viral antigens than that can now be

produced by the available recombinants. For these reasons, during the initial phase of this study we have targeted the goal of separately expressing authentic envelope and NS1 glycoproteins. We have achieved high level production of these dengue proteins using a high yield baculovirus expressing vector. Biochemical characterization of several dengue protein products has also been completed.

RESULTS

(a) Expression of authentic dengue type 4 virus envelope and nonstructural NS1 glycoproteins

Earlier we produced a fusion dengue E glycoprotein that contained the 71 N-terminal amino acids of RSV G glycoprotein fused to amino acids 1-456 (93%) of dengue type 4 E. Immunization of monkeys with the baculovirus recombinant that expressed this dengue E fusion protein induced only partial resistance to challenge with homotypic dengue virus. Hence we felt it would be desirable to evaluate a non-fusion construct of E that expresses authentic E glycoprotein. For this purpose, the dengue DNA fragment that codes for amino acids 1-456 of E plus the predicted N-terminal hydrophobic signal sequence of E (amino acids 265-279 of the dengue 4 polyprotein sequence) preceded by a start codon was obtained from the intermediate vaccinia virus transfer vector constructed earlier (4). This DNA construct was extended to include the coding sequence for the remaining C-terminal 38 amino acids of E plus the first 4 amino acids of NS1 followed by a stop codon. The resulting DNA sequences were inserted into baculovirus plasmid vector pVL 941 (kindly provided by Dr. M. Summers, Texas A & M University, College Station, Texas). The recombinant DNA was recombined into the genome of wild-type Autographa californica mononuclear polyhedrosis virus (ACMNPV) replacing the polyhedrin coding sequence. A recombinant baculovirus was selected and purified from the wild-type ACMNPV after serial-dilution passage and visual selection of virus

plaques lacking polyhedrin. This recombinant virus expressed dengue 4 E as detected by an indirect immunofluorescence assay (IFA) using dengue hyperimmune mouse ascitic fluid (HMAF). This recombinant virus was designated b(DEN4, 100%E).

Proper synthesis of dengue virus NS1 has been studied in the laboratory using vaccinia virus as a vector. We found that the 24 hydrophobic amino acids preceding NS1 and the downstream NS2A sequences were required for authentic synthesis of dengue virus NS1 (Falgout, et al. 1989). DNA sequences coding for dengue 4 NS1-NS2A were prepared from pSC11-NS1-NS2A that had been used for construction of the recombinant vaccinia virus. The DNA fragment was inserted into the baculovirus cloning vector and recombinant plasmid pVL941 NS1-NS2A was isolated. The recombinant baculovirus that contained the DNA insert was designated b(DEN4, NS1-NS2A) was constructed and isolated from wild type baculovirus by serial dilution-passage and plaque purification. IFA was used to identify the dengue virus product expressed in recombinant-infected cells.

(b) Analysis of full-length dengue 4 E and NS1 expressed by recombinant baculoviruses

To verify the dengue protein product expressed by recombinant b(DEN4, 100%E), insect sf9 cells were infected with this recombinant, labeled with ³⁵S-methionine, and lyzed in RIPA buffer (1% sodium deoxycholate, 1% NP-40, 0.1% sodium dodecylsulfate, 0.1M Tris-HCl, PH 7.5, 0.15M NaCl). The radio-

labeled lysate was prepared for immunoprecipitation followed by separation on SDS-polyacrylamide gel. The results showed that a labeled protein with a molecular weight of 55-60 kilodaltons (Kd) predicted for the glycosylated form of dengue E was produced.

Insect sf9 cells were also infected with b(DEN4, NS1-NS2A), radio-labeled, and the lysate prepared for immunoprecipitation using HMAF. Analysis of the immunoprecipitate by polyacrylamide gel electrophoresis revealed a protein band of 40-44 Kd predicted for the NS1 glycoprotein. This confirmed that properly cleaved dengue virus NS1 was made during infection of insect cells with the recombinant construct. The results of this analysis indicate that separate expression of dengue type 4 virus E and NS1 glycoproteins has been achieved using the high yielding baculovirus-insect cell system. This initial success has set the stage for further extension of the proposed studies concerning the production of protective antigens belonging to the remaining three dengue virus serotypes.

(c) Construction of recombinant baculovirus expressing a high level of dengue 4 NS1

Dr. H. Hori of the laboratory studied the amino acid sequence at the NS1-NS2A juncture of dengue virus that is required for specific cleavage effected by the cis-acting function of NS2A. During this study it was observed that recombinant vaccinia virus v(DEN 4, NS1) containing dengue type 4 virus cDNA that codes for the N-terminal signal and the entire

length of the NS1 sequence produced the NS1 glycoprotein at a level 2-3 fold higher than that expressed by recombinant v(DEN 4, NS1-NS2A) which contained NS2A (Hori and Lai, unpublished observation). Although the reason for the increased synthesis of NS1 is not known, we speculate that proteolytic cleavage of polyprotein NS1-NS2A may be inefficient, thus retarding the synthesis of NS1. Since it was desirable to increase the production of NS1, the DNA fragment that codes for the full-length NS1 was prepared and used for construction of a recombinant baculovirus expressing NS1 in the absence of downstream NS2A. This recombinant baculovirus, designated b(DEN 4, NS1) was isolated using the methodology just described. This recombinant DNA strategy for increased expression of dengue 4 NS1 was also adopted for construction of recombinant baculoviruses expressing the NS1 glycoproteins of other dengue virus serotypes.

(d) Construction of recombinant baculovirus expressing
dengue 2 E or NS1 glycoproteins

The dengue virus subgroup of the flavivirus family consists of four serotypes (type 1 to type 4), all of which cause dengue epidemics in many tropical and subtropical areas. There is a high degree of conservation of the amino acid sequences among the four dengue viruses. Amino acid homology of E sequences among different dengue serotype viruses ranges from 62 to 70%. Likewise, amino acid homology of NS1 sequences among different

dengue viruses ranges from 66-73%. These similarities suggest that vaccine strategies developed for dengue type 4 virus should be applicable to the other three dengue virus serotypes. Also, there is a concern about immune enhancement as the underlying cause for severe dengue. Thus, the current strategy for immunization against dengue favors the use of a tetravalent vaccine that contains protective antigens of all four serotype viruses.

As an initial step in this direction, we constructed a recombinant baculovirus expressing dengue type 2 E or NS1 glycoprotein. cDNA fragments of dengue type 2 virus (S1 candidate vaccine strain derived from the PR159 isolate), cloned and sequenced in Dr. Strauss' laboratory (California Institute of Technology, Pasadena, CA), were kindly provided by Dr. Strauss through Dr. Putnak (Walter Reed Army Institute of Research, Washington, D.C.). Clone E8 was the source for E DNA. Dr. Bray in the laboratory constructed a cDNA sequence coding for the 15 amino acid N-terminal signal and the entire length of E (495 amino acids) (10). In order to construct recombinant baculovirus, the E DNA construct was inserted into the intermediate baculovirus vector, pBlueBac (In Vitrogen Corp., San Diego, CA), which contains a lacZ sequence for visual selection of the recombinant virus. The recombinant virus, designated b(DEN2, 100%E) expressed the encoded dengue virus protein as detected by IFA.

In order to verify the expression of dengue 2 NS1, insect sf9 cells were infected with b(DEN2, NS1), labeled with ³⁵S-methionine, lysed in R1PA buffer, and the lysate prepared for analysis of dengue NS1 by immunoprecipitation. Analysis of the immunoprecipitate by polyacrylamide gel electrophoresis showed that a protein approximately 40-44 Kd of the size predicted for dengue NS1 was detected. The estimated molecular size suggested that the NS1 product was glycosylated consistent with the result obtained earlier. This study showed that recombinant baculovirus b(DEN2, NS1) expressed apparently authentic NS1 of dengue 2 virus. Similarly, analysis of dengue 4 NS1 produced by recombinant b(DEN4, NS1), another variant of recombinant baculovirus expressing dengue 4 NS1, was also completed. These studies showed that a protein band with a molecular size approximately 40-44 Kd was made in recombinant b(DEN 4, NS1) infected cells.

(e) Dengue virus NS1 expressed by recombinant baculovirus was not detected extracellularly.

It has been reported that a small fraction of dengue NS1 is secreted into the medium during dengue virus infection of cultured cells (11). We have shown earlier that extracellular dengue virus NS1 was detected at a low level (<2%) in recombinant vaccinia virus v(NS1-NS2A) infected cells, similar to that found during dengue virus infection (Falgout and Lai, unpublished observation). Extracellularly secreted NS1 migrated slower than

did the intracellular NS1 indicating that additional glycosylation had occurred during its transfer through the exocytic pathway. As part of our analysis of dengue type 2 or type 4 NS1 produced by recombinant baculovirus the medium fraction of ^{35}S -methionine labelled-infected cells was also immunoprecipitated and separated by polyacrylamide gel electrophoresis. The results showed that extracellular NS1 was not detected by immunoprecipitation.

(f) Construction of recombinant baculovirus expressing highly immunogenic E

Recent results obtained from our laboratory showed that several C-terminally truncated E's, approximately 80% in length, exhibit increased immunogenicity in mice (12). Unlike full-length E, these truncated E's were detected on the cell surface and secreted extracellularly. In addition to being more immunogenic, a significant fraction of the E product was secreted extracellularly. Extracellularly secreted 80%E also possesses an advantage over intracellular full-length E in the greater ease with which it can be purified. For these reasons, we have initiated studies to construct recombinant baculovirus for the production of 80%E truncated at the C-terminus. Initial success has been made in the construction of recombinant DNA and the generation of recombinant baculovirus. Experiments to analyze quantitatively the E product expressed by the recombinant are currently underway. We plan to evaluate the immunogenicity and

protective efficacies of the full-length and the C-terminally truncated E's in mice. The level of antibody response in immunized mice will be determined by serologic analysis. The subunit protein products that induce an increased antibody response will be further evaluated in primates which are the best available experimental surrogates for human dengue virus infection.

CONCLUSIONS

The envelope (E) and NS1 nonstructural glycoproteins of dengue virus have been identified as independent protective antigens in mice during studies in which these glycoproteins expressed singly or together by recombinant vaccinia virus or baculovirus were evaluated for their protective immunity against lethal intracerebral dengue challenge. As proposed, the research goals of this study are to; (1) produce authentically processed dengue subunit protective antigens using the high yielding baculovirus-insect cell expression system; and (2) design recombinant DNA constructs that code for highly immunogenic protein products, and achieve a high level expression of these products.

During the initial phase of this study we have completed construction of recombinant baculoviruses that separately express full-length E or NS1 glycoprotein of dengue type 2 and type 4 viruses. Radio-immunoprecipitation was performed to analyze the dengue product in the lysate of recombinant virus infected cells. The results showed that insect cells infected with recombinant b(DEN 4, 100%E) produced a protein with molecular weight of 55-60 kilodalton (Kd) as predicted for the glycosylated form of dengue E glycoprotein. Similarly, recombinant b(DEN 4, NS1) or b(DEN 2, NS1) produced a protein in infected insect cells that was approximately 40-44 Kd, the size predicted for the dengue NS1 glycoprotein. In the next phase of this study we plan to prepare lysates of insect cells infected with various recombinant

baculoviruses. These lysates will be analyzed quantitatively and used for evaluation of immunogenicity of the expressed dengue protein products in mice. These studies will allow us to determine separately the protective efficacy afforded by each of these dengue virus proteins, and therefore, select the most immunogenic as well as the most protective recombinant products for further evaluation in primates.

REFERENCES

1. Bancroft, W.H., McCown, J.M., Lago, P.M. Brandt, W.E., and Russell, P.K. (1979) Pan Am. Hlth. Org. Sci. Publ. 375, 175-178.
2. Henschel, E.A., Gentry, M.K., McCown, J.M., and Brandt, W.E. (1982) Am. J. Trop. Med. Hyg. 31, 548-555.
3. Zhao, B., Prince, G., Horswood, R., Eckels, K., Summer, P., Chanock, R.M., Lai, C.J. (1987) J. Virol. 61, 4019-4022.
4. Bray, M., Zhao, B., Markoff, L., Eckels, K., Chanock, R.M., Lai, C.J. (1989) J. Virol. 63, 2853-2856.
5. Zhang, Y.M., Hayes, E.P., McCarty, T.C., Dubois, D.R., Summer, P.L., Eckels, K.H., Chanock, R.M., Lai, C.J. (1988) J. Virol. 62, 3207.
6. Lai, C.J., Zhang, Y.-M., Bray, M., Chanock, R., and Eckels, K.H. (1989) pp. 351-356. In R. Lerner, H. Ginsberg, R.M. Chanock, and F. Brown (ed.), Vaccine 89: Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
7. Falgout, B., Chanock, R.M., Lai, C.J. (1989) J. Virol. 63, 1852-1860.
8. Falgout, B., Bray, M., Schlesinger, J.J., Lao, C.J. (1990) J. Virol. 64, 4356-4363.
9. Lai, C.J., Zhang, Y.M., Men, R., Bray, M., Chanock, R.M., Dubois, D.R., and Eckels, K.H. (1990) pp. 119-124. In F. Brown, R.M. Chanock, H.S. Ginsberg, and R. Lerner (ed.)

Vaccines 90: Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

10. Hahn, Y.S., Galler, R., Hunkapiller, T., Dalrymple, J.M., Strauss, J.H., and Strauss, E.G. (1988) Virology 162, 167-180.
11. Winkler, G., Randolph, V.B., Cleaves, G.R., Ryan, T.E., and Stollar, V. (1989) Virology 171, 302-305.
12. Men, R., Bray, M., and Lai, C.J. (1991) J. Virol. 65, 1400-1407.